Eli Lilly's $23 Billion Quarter: Can Foundayo Extend the Obesity Boom?
Eli Lilly stock analysis: Q2 2026 sales, Mounjaro, Zepbound, Foundayo, obesity-drug pricing, retatrutide and the investment risks ahead.
EXPLORE A LITTLE FURTHER
Lly
2 stories from the Compound journal.
Eli Lilly''s Foundayo Wins European Backing: What the Oral GLP-1 Means for LLY Investors
Foundayo wins positive European regulatory opinion. Analyse Eli Lilly's 2026 sales, Mounjaro, Zepbound, GLP-1 pricing and risks for LLY investors.